Tauopathy and Alzheimer disease: A full degenerating process;Tauopathie et maladie d'Alzheimer, un processus dégéné ratif à part entière

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 4, Issue 4, 2006, Pages 261-273

  Buée, Luc ^a   Delacourte, André ^a  

^a NONE

Author keywords

Alternative splicing; Alzheimer disease; Microtubule associated proteins; Neuron; Phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; GENE MUTATION; HEREDITY; HUMAN; NEUROFILAMENT; PATHOGENESIS; REVIEW; TAUOPATHY;

AGED; AGING; ALZHEIMER DISEASE; BRAIN; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NERVE DEGENERATION; NEURONS; PHOSPHORYLATION; POINT MUTATION; TAU PROTEINS;

EID: 33846023342     PISSN: 17601703     EISSN: None     Source Type: Journal    
DOI: 10.1684/pnv.2006.0022     Document Type: Review

References (72)

1. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 1975; 72: 1858-62.
2. Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 1977; 116: 207-25.
3. Brion JP. Immunological determinants of tau proteins are present in neurofibrillary tangles of Alzheimer's disease. Arch Biol (Brux) 1985; 95: 229-35.
4. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
5. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-59.
6. Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 2005; 1739: 179-97.
7. Terry RD. Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 1118-9.
8. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimer's Dis 2006; 9 (Suppl. 3): 151-3.
9. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, et al. Non overlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002; 59: 398-407.
10. Delacourte A, Defossez A. Alzheimer's disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 1986; 76: 173-86.
11. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519-26.
12. Wei ML, Memmott J, Screaton G, Andreadis A. The splicing determinants of a regulated exon in the axonal MAP tau reside within the exon and in its upstream intron. Brain Res Mol Brain Res 2000; 80: 207-18.
13. Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, et al. Mitotic-like tau phosphorylation by p25/Cdk5 kinase complex. J Biol Chem 2003; 278: 34026-34.
14. Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem 1995; 270: 18917-22.
15. Mailliot C, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L. Alzheimer-specific epitope of AT100 in transfected cell lines with tau: toward an efficient cell model of tau abnormal phosphorylation. Neurosci Lett 1998; 255: 13-6.
16. Bussière T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP, et al. Phosphorylated serine 422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol (Berl) 1999; 97: 221-30.
17. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005; 38: 746-54.
18. Cripps D, Thomas S, Jeng Y, Yang F, Davies P, Yang A. Alzheimer's disease-specific conformation of hyperphosphorylated PHF-tau is polyubiquitinated through lys-48, lys-11, and lys-6 ubiquitin conjugation. J Biol Chem 2006; 281: 10825-38.
19. Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buée L, et al. Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J Neurochem 1997; 69: 834-44.
20. Buée-Scherrer V, Buée L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, et al. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol 1995; 146: 924-32.
21. Buée-Scherrer V, Buée L, Leveugle B, Perl DP, Vermersch P, Hof PR, et al. Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997; 42: 356-9.
22. Hof PR, Nimchinsky EA, Buée-Scherrer V, Buée L, Nasrallah J, Hottinger AF, et al. Amyotrophic lateral sclerosis/parkinsonism- dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol (Berl) 1994; 88: 397-404.
23. Hof PR, Bouras C, Perl DP, Morrison JH. Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease. Acta Neuropathol (Berl) 1994; 87: 115-24.
24. Buée-Scherrer V, Hof PR, Buée L, Leveugle B, Vermersch P, Perl DP, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol (Berl) 1996; 91: 351-9.
25. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8: 393-9.
26. Sergeant N, David JP, Lefranc D, Vermersch P, Wattez A, Delacourte A. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett 1997; 412: 578-82.
27. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998; 43: 193-204.
28. Mailliot C, Sergeant N, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 1998; 433: 201-4.
29. Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F. Abnormal tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol (Berl) 1991; 81: 591-6.
30. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem 1999; 72: 1243-9.
31. Rademakers R, Melquist S, Cruts M, Theuns J, Del-Favero J, Poorkaj P, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005; 14: 3281-92.
32. Van Swieten JC, Rosso SM, van Herpen E, Kamphorst W, Ravid R, Heutink P. Phenotypic variation in frontotemporal dementia and parkinsonism linked to chromosome 17. Dement Geriatr Cogn Disord 2004; 17: 261-4.
33. Vermersch P, Sergeant N, Ruchoux MM, Hofmann-Radvanyi H, Wattez A, Petit H, et al. Specific tau variants in the brains of patients with myotonic dystrophy. Neurology 1996; 47: 711-7.
34. Sergeant N, Sablonniere B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001; 10: 2143-55.
35. Leroy O, Wang J, Maurage CA, Parent M, Cooper TA, Buée L, et al. Brain-specific change in alternative splicing of tau exon 6 in myotonic dystrophy type 1. Biochim Biophys Acta 2006; 1762: 460-7.
36. Leroy O, Dhaenens CM, Schraen-Maschke S, Belarbi K, Delacourte A, Andreadis A, et al. ETR-3 represses tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res 2006; 84: 852-9.
37. Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004; 61: 1943-7.
38. Maurage CA, Udd B, Ruchoux MM, Vermersch P, Kalimo H, Krahe R, et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005; 65: 1636-8.
39. Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem 2002; 81: 663-72.
40. Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 2006; 65: 278-88.
41. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301I tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-5.
42. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
43. Goldsbury C, Mocanu MM, Thies E, Kaether C, Haass C, Keller P, et al. Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic 2006; 7: 873-88.
44. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
45. Delacourte A, Buée L. Modélisation de la maladie d'Alzheimer: un parcours semé d'embûches. Psychol Neuropsychiatr Vieil 2005; 3: 261-70.
46. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169: 599-616.
47. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25: 402-5;
48. Erratum in Nat Genet 2000; 26: 127.
49. Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276: 529-34.
50. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24: 1079-85.
51. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005; 102: 227-31.
52. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990-5.
53. Annas P, Schröder J, Fröhlich L, Riepe M, Kraft I, Gasser T, et al. A randomised, single-blind, placebo-controlled, multicentre study to investigate the pharmacodynamic effects of lithium on GSK3 activity in patients with mild Alzheimer's disease. Alzheimer's & Dementia 2006; 2: S257.
54. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006; 103: 9673-8.
55. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005; 22: 1942-50.
56. Hamdane M, Delobel P, Sambo AV, Smet C, Begard S, Violleau A, et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem Pharmacol 2003; 66: 1619-25.
57. Hamdane M, Smet C, Sambo AV, Leroy A, Wieruszeski JM, Delobel P, et al. Pin1: a therapeutic target in Alzheimer neurodegeneration. J Mol Neurosci 2002; 19: 275-87.
58. Smet C, Duckert JF, Wieruszeski JM, Landrieu I, Buée L, Lippens G, et al. Control of protein-protein interactions: structure-based discovery of low molecular weight inhibitors of the interactions between Pin1 WW domain and phosphopeptides. J Med Chem 2005; 48: 4815-23.
59. Galas MC, Dourlen P, Begard S, Ando K, Blum D, Hamdane M, et al. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem 2006; 281: 19296-304.
60. Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, Ando K, et al. Pin1 allows for differential tau dephosphorylation in neuronal cells. Mol Cell Neurosci 2006; 32: 155-60.
61. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005; 280: 3628-35.
62. Pickhardt M, von Bergen M, Gazova Z, Hascher A, Biernat J, Mandelkow EM, et al. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005; 2: 219-26.
63. Lippens G, Wieruszeski JM, Leroy A, Smet C, Sillen A, Buée L, et al. Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites. ChemBioChem 2004; 5: 73-8.
64. Smet C, Leroy A, Sillen A, Wieruszeski JM, Landrieu I, Lippens G. Accepting its random coil nature allows a partial NMR assignment of the neuronal tau protein. ChemBioChem 2004; 5: 1639-46.
65. Sillen A, Leroy A, Wieruszeski JM, Loyens A, Beauvillain JC, Buée L, et al. Regions of tau implicated in the paired helical fragment core as defined by NMR. ChemBioChem 2005; 6: 1849-56.
66. Lippens G, Sillen A, Smet C, Wieruszeski JM, Leroy A, Buée L, et al. Studying the natively unfolded neuronal tau protein by solution NMR spectroscopy. Protein Pept Lett 2006; 13: 235-46.
67. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006; 281: 1205-14.
68. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 2005; 44: 10227-37.
69. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S, et al. Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet 2006; 38: 1032-7.
70. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.
71. Erratum in Lancet Neurol 2006; 5: 293.
72. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-45.